1) Strategy & Leadership
- Cardinal Health concluded fiscal year 2026 with strong execution and broad-based performance, particularly in Pharmaceutical and Specialty Solutions.
- The company emphasized its commitment to operational excellence and strategic long-term investments, positioning for growth in fiscal 2027 and beyond.
- CEO Jason Hollar highlighted the importance of simplifying operations and enhancing customer service capabilities through investments in automation and technology.

2) Financial & Segment Results
- Total revenue for Q4 2026 was $63.7 billion, a 6% increase YoY, with operating earnings growing 30% and EPS increasing 40% to $2.91.
- The Pharmaceutical segment revenue grew 6% to $58.8 billion, with segment profit increasing 21% to $645 million, driven by strong demand and brand-to-generic conversions.
- The Global Medical Products and Distribution (GMPD) segment reported a 2% decline in revenue to $3.1 billion, impacted by tariff-related payables, but profit increased to $150 million, aided by a one-time $100 million tariff refund.
- Other growth businesses generated $1.7 billion in revenue (7% growth) and $183 million in profit (14% growth).

3) Problems / Headwinds
- The company faced headwinds from IRA WACC changes, which impacted revenue growth in the Pharmaceutical segment, estimated at around 500 basis points.
- GMPD experienced a decline in revenue due to expected payables related to tariff refunds and lower distribution volumes, although the underlying operational performance showed improvement.
- Rising input costs, particularly in oil and petroleum products, are being monitored closely, with potential impacts on profitability if they remain elevated.

4) Operational or Product Plans
- Cardinal Health is focused on expanding its Specialty business and enhancing its capabilities in biopharma solutions, with plans to support innovative therapies entering the market.
- The company is investing in automation and technology to drive efficiencies and improve service levels, particularly in its at-home solutions and logistics businesses.
- Strategic acquisitions, such as the recent purchase of Strive Medical and the Diabetes Health segment of AdaptHealth, are expected to contribute to growth and operational synergies.

5) Guidance & Outlook / Investor Angle
- For fiscal year 2027, Cardinal Health is guiding for EPS growth of 13% to 15%, with expected revenue growth of 3% to 5% in the Pharmaceutical segment and 2% to 4% in GMPD.
- The company aims to generate $3.5 billion to $4 billion in adjusted free cash flow, maintaining a disciplined capital allocation strategy with a focus on returning capital to shareholders, including a $1 billion share repurchase program.
- Long-term EPS growth guidance remains at 12% to 14% per year, reflecting confidence in the business's growth trajectory and balance sheet strength.

Bottom line: Cardinal Health's strong performance in fiscal 2026, driven by robust demand and strategic investments, positions the company well for continued growth in fiscal 2027, with a focus on enhancing operational efficiencies and returning capital to shareholders.